AU7989400A - Compounds and methods - Google Patents

Compounds and methods

Info

Publication number
AU7989400A
AU7989400A AU79894/00A AU7989400A AU7989400A AU 7989400 A AU7989400 A AU 7989400A AU 79894/00 A AU79894/00 A AU 79894/00A AU 7989400 A AU7989400 A AU 7989400A AU 7989400 A AU7989400 A AU 7989400A
Authority
AU
Australia
Prior art keywords
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU79894/00A
Other languages
English (en)
Inventor
Joseph P. Marino Jr.
Scott K. Thompson
Daniel Frank Veber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU7989400A publication Critical patent/AU7989400A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU79894/00A 1999-10-01 2000-09-29 Compounds and methods Abandoned AU7989400A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15728699P 1999-10-01 1999-10-01
US60157286 1999-10-01
PCT/US2000/026951 WO2001024796A1 (en) 1999-10-01 2000-09-29 1,2,4-triazole derivatives, composition, process of making and methods of use

Publications (1)

Publication Number Publication Date
AU7989400A true AU7989400A (en) 2001-05-10

Family

ID=22563095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79894/00A Abandoned AU7989400A (en) 1999-10-01 2000-09-29 Compounds and methods

Country Status (5)

Country Link
US (1) US7304082B2 (enExample)
EP (1) EP1223932A4 (enExample)
JP (1) JP2003510359A (enExample)
AU (1) AU7989400A (enExample)
WO (1) WO2001024796A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078697A1 (en) * 2001-03-29 2002-10-10 Smithkline Beecham Corporation Compounds and methods
WO2003083068A2 (en) * 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
AR040847A1 (es) * 2002-08-09 2005-04-20 Astrazeneca Ab 1,2,4-oxadiazoles como moduladores de receptores de glutamato metabotropicos, para el tratamiento de desordenes neurologicos y psiquiatricos
FR2862060A1 (fr) * 2003-11-06 2005-05-13 Galderma Res & Dev Procede de synthese en phase solide de composes de types sulfures de diaryle.
AU2007267803B2 (en) * 2006-05-25 2011-08-25 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
WO2009003110A2 (en) 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CN103249735B (zh) * 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
US20130316994A1 (en) 2010-11-29 2013-11-28 Zafgen, Inc. Methods of Reducing Risk of Hepatobiliary Dysfunction During Rapid Weight Loss with METAP-2 Inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
KR20140006888A (ko) 2011-01-26 2014-01-16 자프겐 인크. 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법
CA2835261C (en) 2011-05-06 2019-06-04 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112013028666A2 (pt) 2011-05-06 2017-08-08 Zafgen Inc compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
AU2013259617A1 (en) 2012-05-08 2014-11-27 Zafgen, Inc. Treating hypothalamic obesity with MetAP2 inhibitors
MX356755B (es) 2012-05-09 2018-06-11 Zafgen Inc Compuestos de tipo fumagilol y metodos para su elaboración y uso.
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
JP2015536981A (ja) 2012-11-05 2015-12-24 ザフゲン，インコーポレイテッド 三環式化合物ならびにその製造および使用方法
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
CN105228610A (zh) 2013-03-14 2016-01-06 扎夫根股份有限公司 治疗肾疾病和其它病症的方法
WO2015089800A1 (en) 2013-12-19 2015-06-25 Eli Lilly And Company Fluorophenyl pyrazol compounds
EP3154634B1 (en) * 2014-06-12 2021-02-24 Université de Lille Imidazol- or 1,2,4-triazol-derivatives and their use
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
MA52489A (fr) * 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55120571A (en) * 1979-03-02 1980-09-17 Glaxo Group Ltd Heterocyclic derivative
CH655104A5 (fr) * 1980-02-28 1986-03-27 Glaxo Group Ltd Derives heterocycliques triazoliques, procedes pour leur preparation et compositions pharmaceutiques les comportant.
HU191475B (en) * 1982-09-01 1987-02-27 Gyogyszerkutato Intezet Process for producing new acylized 1,2,4-triazole derivatives
US4760448A (en) * 1987-05-04 1988-07-26 Sencore, Inc. Method of measuring amplitude variations of a video carrier and apparatus therefor
JPH01160972A (ja) * 1987-12-18 1989-06-23 Tsumura & Co １，２，４−トリアゾール誘導体及びそれを有効成分として含有する抗潰瘍剤
DE4142366A1 (de) 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9207396D0 (en) 1992-04-03 1992-05-13 Merck Sharp & Dohme Therapeutic agents
DE4424787A1 (de) 1994-07-14 1996-01-18 Bayer Ag Substituierte Aryliminoheterocyclen
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
WO1996016971A1 (de) * 1994-11-29 1996-06-06 Lonza Ag Verfahren zur herstellung optisch aktiver metallocenylphosphine
US5798374A (en) * 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6207704B1 (en) * 1997-06-09 2001-03-27 Massachusetts Institute Of Technology Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof
DE19922443A1 (de) * 1999-05-07 2000-11-09 Basf Ag Verwendung von Dopamin-D3-Rezeptorliganden zur Herstellung von Arzneimittel für die Behandlung von Nierenfunktionsstörungen
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
WO2001036404A1 (en) 1999-11-19 2001-05-25 Smithkline Beecham Corporation Compounds and methods
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
AU2001231154A1 (en) * 2000-01-24 2001-07-31 Adherex Technologies Inc. Peptidomimetic modulators of cell adhesion
AU2001253418A1 (en) * 2000-04-12 2001-10-30 Smith Kline Beecham Corporation Compounds and methods
WO2002005804A1 (en) 2000-07-19 2002-01-24 Smithkline Beecham Corporation Compounds and methods
JP2005506299A (ja) * 2001-03-29 2005-03-03 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2004525942A (ja) * 2001-03-29 2004-08-26 スミスクライン・ビーチャム・コーポレイション 化合物および方法
JP2004535377A (ja) 2001-04-03 2004-11-25 スミスクライン・ビーチャム・コーポレイション Ｍｅｔａｐ２を阻害する方法
WO2003031434A1 (en) * 2001-10-12 2003-04-17 Smith Kline Beecham Corporation Compounds and methods
AU2002359694A1 (en) 2001-12-14 2003-06-30 Smithkline Beecham Corporation Compounds and methods
JP2003281388A (ja) * 2002-03-25 2003-10-03 Hitachi Ltd 自動取引装置
WO2003083068A2 (en) * 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
US20040116490A1 (en) * 2002-03-28 2004-06-17 Marino Jr. Joseph P. Compounds and methods

Also Published As

Publication number Publication date
US7304082B2 (en) 2007-12-04
JP2003510359A (ja) 2003-03-18
WO2001024796A8 (en) 2001-05-17
WO2001024796A1 (en) 2001-04-12
EP1223932A4 (en) 2003-01-15
EP1223932A1 (en) 2002-07-24
US20050267185A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
AU3215500A (en) Compounds and methods
AU1173201A (en) Skin-gripper
AU3092999A (en) Digital-timeshare-exchange
EP1223932A4 (en) COMPOUNDS AND METHODS
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2678800A (en) Modified calycins
AU2001243394A1 (en) Compounds and methods
AU7514700A (en) Cyanopiperidines
AU5967600A (en) Candystraw
AU4115400A (en) Short-circuiter
AU6335000A (en) Depthimeter
AUPQ872300A0 (en) Compounds and methods
AU2023701A (en) Sketcher
AU1083501A (en) Antibiotic-metal complex and methods
AU2804600A (en) Arylaminoalkylamides
AU2699800A (en) Organoceramics
AU6440900A (en) Homogentisate-dioxygenase
AU2001278951A1 (en) Compounds and methods
AU6098300A (en) Follistatin-3
AU4916900A (en) Benzofuranylsulfonates
AU4561600A (en) Benzofuranylaminoalcohols
AU2002235277A1 (en) Compounds and methods
AU1901801A (en) Glucofuranoses
AU1915601A (en) Periotome

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase